Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Author:

Ugarte-Gil Manuel FranciscoORCID,Hanly John,Urowitz MurrayORCID,Gordon Caroline,Bae Sang-CheolORCID,Romero-Diaz Juanita,Sanchez-Guerrero Jorge,Bernatsky SashaORCID,Clarke Ann Elaine,Wallace Daniel JORCID,Isenberg David AlanORCID,Rahman AnisurORCID,Merrill Joan T,Fortin Paul RORCID,Gladman Dafna DORCID,Bruce Ian N,Petri MichelleORCID,Ginzler Ellen M,Dooley Mary Anne,Ramsey-Goldman Rosalind,Manzi Susan,Jönsen Andreas,van Vollenhoven Ronald FORCID,Aranow CynthiaORCID,Mackay Meggan,Ruiz-Irastorza GuillermoORCID,Lim Sam,Inanc MuratORCID,Kalunian Ken,Jacobsen Søren,Peschken Christine,Kamen Diane L,Askanase Anca,Pons-Estel Bernardo A,Alarcón Graciela SORCID

Abstract

ObjectiveTo determine the independent impact of different definitions of remission and low disease activity (LDA) on damage accrual.MethodsPatients with ≥2 annual assessments from a longitudinal multinational inception lupus cohort were studied. Five mutually exclusive disease activity states were defined: remission off-treatment: clinical Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI)-2K=0, without prednisone or immunosuppressants; remission on-treatment: cSLEDAI-2K score=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; low disease activity Toronto cohort (LDA-TC): cSLEDAI-2K score of ≤2, without prednisone or immunosuppressants; modified lupus low disease activity (mLLDAS): Systemic Lupus Erythematosus Disease Activity Index-2K score of 4 with no activity in major organ/systems, no new disease activity, prednisone ≤7.5 mg/day and/or maintenance immunosuppressants; active: all remaining visits. Only the most stringent definition was used per visit. Antimalarials were allowed in all. The proportion of time that patients were in a specific state at each visit since cohort entry was determined. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and multivariable generalised estimated equation negative binomial regression models were used. Time-dependent covariates were determined at the same annual visit as the disease activity state but the SDI at the subsequent visit.ResultsThere were 1652 patients, 1464 (88.6%) female, mean age at diagnosis 34.2 (SD 13.4) years and mean follow-up time of 7.7 (SD 4.8) years. Being in remission off-treatment, remission on-treatment, LDA-TC and mLLDAS (per 25% increase) were each associated with a lower probability of damage accrual (remission off-treatment: incidence rate ratio (IRR)=0.75, 95% CI 0.70 to 0.81; remission on-treatment: IRR=0.68, 95% CI 0.62 to 0.75; LDA: IRR=0.79, 95% CI 0.68 to 0.92; and mLLDAS: IRR=0.76, 95% CI 0.65 to 0.89)).ConclusionsRemission on-treatment and off-treatment, LDA-TC and mLLDAS were associated with less damage accrual, even adjusting for possible confounders and effect modifiers.

Funder

the Department of Education, Universities and Research of the Basque Government

National Institutes of Health

Sandwell and West Birmingham Hospitals NHS Trust

National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility

Centers for Disease Control and Prevention

LUPUS UK

Singer Family Fund for Lupus Research

National Institute for Health Research University College London Hospitals Biomedical Research Centre

Canada Research Chair on Systemic Autoimmune Rheumatic Diseases

Universidad Cientifica del Sur

National Research Foundation of Korea

The Arthritis Society Chair in Rheumatic Diseases

NIHR/Wellcome Trust Manchester Clinical Research Facility

Danish Rheumatism Association

Arthritis Research UK

Novo Nordisk Foundation

NIHR Manchester Biomedical Centre

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3